verify if Sanofi has hired agents in Wall Street to help keep the Geron share price below $5.00!! This will result in a difficulty for Geron to raise more money. Doing so and postponing licensing of Imtelstat even for as little as a month means Sanofi pockets approx $20M through extended sale of its JAK inhibitor!! Do you think big pharmas are playing such games?
First, the ID, "mruyog", extracts a feces-festered fistful of its infamous conjectures from its cheddar-reeking and tightly-impacted colon, and then, asks those assembled to comment on another of its fetid conjectures....this time, of the "big-pharma-game-playing" variety.